Viridian Therapeutics (VRDN) News Today $20.14 -1.50 (-6.93%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2024 EPS Forecast for Viridian Therapeutics Cut by AnalystNovember 16 at 1:17 AM | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 5.8% - Time to Sell?Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8% - Here's What HappenedNovember 15 at 1:13 PM | marketbeat.comFY2024 Earnings Estimate for VRDN Issued By Leerink PartnrsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for Viridian Therapeutics in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will postNovember 15 at 6:04 AM | marketbeat.comWhat is Lifesci Capital's Estimate for VRDN FY2024 Earnings?Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Research analysts at Lifesci Capital lowered their FY2024 EPS estimates for shares of Viridian Therapeutics in a report released on Tuesday, November 12th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earningsNovember 15 at 6:04 AM | marketbeat.comWedbush Has Pessimistic Outlook of VRDN FY2024 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Stock analysts at Wedbush lowered their FY2024 earnings estimates for Viridian Therapeutics in a research report issued on Tuesday, November 12th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($3.97) per shNovember 15 at 6:04 AM | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by AnalystsShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and eight have assigned aNovember 15 at 3:11 AM | marketbeat.comViridian Therapeutics price target raised to $34 from $27 at H.C. WainwrightNovember 15 at 12:21 AM | markets.businessinsider.comViridian Therapeutics: Promising Developments and Strategic Initiatives Drive Buy RatingNovember 15 at 12:21 AM | markets.businessinsider.comQ1 Earnings Estimate for VRDN Issued By WedbushViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at Wedbush issued their Q1 2026 EPS estimates for Viridian Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst L. Chico expects that the company will post earnings per share of ($1.1November 14 at 10:04 AM | marketbeat.comHC Wainwright Raises Viridian Therapeutics (NASDAQ:VRDN) Price Target to $34.00HC Wainwright lifted their target price on Viridian Therapeutics from $27.00 to $34.00 and gave the company a "buy" rating in a research note on Thursday.November 14 at 8:32 AM | marketbeat.comJefferies Releases a Buy Rating on Viridian Therapeutics (VRDN)November 13, 2024 | markets.businessinsider.comViridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Wednesday.November 13, 2024 | marketbeat.comViridian Therapeutics Receives Buy Rating Due to Strong Financial Position and Promising Drug PipelineNovember 13, 2024 | markets.businessinsider.comPositive Outlook for Viridian Therapeutics Driven by Promising VRDN-008 Data and Strategic ExpansionNovember 13, 2024 | markets.businessinsider.comViridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn DataNovember 12, 2024 | finanznachrichten.deViridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year High - Time to Buy?Viridian Therapeutics (NASDAQ:VRDN) Hits New 1-Year High - Here's WhyNovember 11, 2024 | marketbeat.comViridian Therapeutics Insiders Added US$616.3k Of Stock To Their HoldingsOctober 31, 2024 | finance.yahoo.comBuy Rating for Viridian Therapeutics Boosted by Promising VRDN-001 Trial Results and Pipeline PotentialOctober 28, 2024 | markets.businessinsider.comNovo Holdings A S Buys 385,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Novo Holdings A S grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 19.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,385,000 shares of the company's stock after purchasing an additionOctober 27, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Stock Quotes, Forecast and News SummaryOctober 24, 2024 | benzinga.comViridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical ResultsOctober 24, 2024 | msn.comViridian Therapeutics' Superior Prospects Make It A BuyOctober 23, 2024 | seekingalpha.comViridian Therapeutics’ FcRn Inhibitor Potential and Upcoming Data Catalysts Drive Buy RatingOctober 22, 2024 | markets.businessinsider.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from BrokeragesViridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven research firms that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and nine have given a buy ratingOctober 21, 2024 | marketbeat.comSG Americas Securities LLC Sells 29,615 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)SG Americas Securities LLC reduced its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 64.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,441 shares of the company'October 19, 2024 | marketbeat.comState Street Corp's Strategic Reduction in Viridian Therapeutics IncOctober 18, 2024 | finance.yahoo.comViridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week High - Should You Buy?Viridian Therapeutics (NASDAQ:VRDN) Hits New 52-Week High - Here's What HappenedOctober 18, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Millennium Management LLCMillennium Management LLC grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 1,014.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 228,182 shares of the company's stock aOctober 15, 2024 | marketbeat.comDimensional Fund Advisors LP Increases Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Dimensional Fund Advisors LP raised its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 968.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 107,580 shares of the company's stock after aOctober 13, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Up 6.4% - Should You Buy?Viridian Therapeutics (NASDAQ:VRDN) Stock Price Up 6.4% - Should You Buy?October 11, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week High After Insider Buying ActivityViridian Therapeutics (NASDAQ:VRDN) Hits New 12-Month High on Insider Buying ActivityOctober 1, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) COO Purchases $117,050.00 in StockOctober 1, 2024 | insidertrades.comNovo Holdings A S Acquires 900,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Novo Holdings A S increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 81.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,000,000 shares of the company's stock after acquiring an additSeptember 30, 2024 | marketbeat.comShort Interest in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Increases By 30.3%Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) was the target of a significant increase in short interest in September. As of September 15th, there was short interest totalling 10,460,000 shares, an increase of 30.3% from the August 31st total of 8,030,000 shares. Based on an average trading volume of 1,460,000 shares, the short-interest ratio is presently 7.2 days.September 27, 2024 | marketbeat.comMaverick Capital Ltd. Has $43.04 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Maverick Capital Ltd. grew its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 22.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,307,945 shares of the company'September 27, 2024 | marketbeat.comForecasting The Future: 13 Analyst Projections For Viridian TherapeuticsSeptember 26, 2024 | benzinga.comBuy Rating for Viridian Therapeutics: Leading the TED Market with Innovative SC Treatment VRDN-003September 26, 2024 | markets.businessinsider.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and ninSeptember 26, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Up 2.3%Viridian Therapeutics (NASDAQ:VRDN) Trading Up 2.3%September 25, 2024 | marketbeat.comAffinity Asset Advisors LLC Invests $1.95 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Affinity Asset Advisors LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 150,000 shares oSeptember 25, 2024 | marketbeat.comGreat Point Partners LLC Sells 835,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Great Point Partners LLC lessened its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 62.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 500,000 shares of the company's stock after sellSeptember 24, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 4.9%Viridian Therapeutics (NASDAQ:VRDN) Shares Down 4.9%September 23, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Rhumbline AdvisersRhumbline Advisers grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 34.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 90,826 shares of the company's stock after purchasing an additional 23,305 shares during theSeptember 23, 2024 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Viridian Therapeutics (VRDN)September 20, 2024 | markets.businessinsider.comRoyal Bank of Canada Reiterates Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN)Royal Bank of Canada restated an "outperform" rating and set a $44.00 target price on shares of Viridian Therapeutics in a research note on Thursday.September 19, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Up Following Insider Buying ActivityViridian Therapeutics (NASDAQ:VRDN) Shares Gap Up After Insider Buying ActivitySeptember 18, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Director Fairmount Funds Management Llc Purchases 1,600,000 SharesSeptember 18, 2024 | insidertrades.comBank of New York Mellon Corp Has $2.72 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Bank of New York Mellon Corp grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 37.4% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 208,676 shares of the company's stock after buyinSeptember 16, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Given New $44.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada raised their price objective on shares of Viridian Therapeutics from $35.00 to $44.00 and gave the stock an "outperform" rating in a report on Friday.September 13, 2024 | marketbeat.comB. Riley Comments on Viridian Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:VRDN)Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Investment analysts at B. Riley raised their FY2024 earnings per share estimates for shares of Viridian Therapeutics in a research note issued on Tuesday, September 10th. B. Riley analyst K. Patel now expects that the company will earn ($3September 13, 2024 | marketbeat.com Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now VRDN Media Mentions By Week VRDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼0.220.56▲Average Medical News Sentiment VRDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼324▲VRDN Articles Average Week Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARWR News Today OPGN News Today PMD News Today PACS News Today HIMS News Today SHC News Today OPCH News Today SGRY News Today BTSG News Today GH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
